Phase II assessment of recombinant leukocyte A interferon with difluoromethylornithine in disseminated malignant melanoma

E. T. Creagan, H. J. Long, D. L. Ahmann, D. J. Schaid

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Sixteen patients with advanced melanoma received IFN-α2A, 36 x 106 U/m2 i.m., on days 3-7 with 2.25 g/m2 DFMO p.o. on days 1-7. We observed no objective regressions. Median time to progression was 1.2 months with a median survival of 5.2 months. A flu-type syndrome was the predominant sequela. From the dose and schedule that we utilized, this regimen holds little promise against disseminated malignant melanoma.

Original languageEnglish (US)
Pages (from-to)218-220
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume13
Issue number3
DOIs
StatePublished - Jan 1 1990

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II assessment of recombinant leukocyte A interferon with difluoromethylornithine in disseminated malignant melanoma'. Together they form a unique fingerprint.

Cite this